Redeye provides a short research update following the positive phase IIb results with lead candidate pudafensine published by Initiator Pharma last week. Overall, we are encouraged to learn that the candidate demonstrated statistically significant and clinically relevant efficacy. We raise our base case valuation to SEK24 as we see an increased likelihood of approval (LoA) following the results.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/